Oncology Grand Rounds Series: Part 2 — Cancer Immunotherapy

Oncology Grand Rounds Series: Part 2 — Cancer Immunotherapy
A satellite symposium held at the 2017 ONS Annual Congress

Oncology Grand Rounds Series:
Part 2 — Cancer Immunotherapy

01:26 minutes | 1.6 Contact hours.

Video proceedings from the second in a series of 7 integrated symposia held at the 2017 ONS Annual Congress. Featuring perspectives from Ms Kimberly Allman, Dr Johanna C Bendell, Ms Susan J McCall and Dr Daniel P Petrylak.

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CNE credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Introduction
59-year-old woman with recurrent Hodgkin lymphoma and currently no evidence of disease on expectant observation
68-year-old woman with metastatic urothelial carcinoma enrolled on a Phase II study of atezolizumab
60-year-old man with metastatic renal cell carcinoma (mRCC), intractable diarrhea and arthralgia
64-year-old man with mRCC who received 75 infusions of nivolumab before developing toxicities
58-year-old man with recurrent Hodgkin lymphoma and persistent, worsening skin rash while receiving nivolumab
49-year-old man with mRCC who developed xerostomia, orthostasis, fatigue, weakness, cognitive changes and erectile dysfunction on ipilimumab/nivolumab
Review additonal nursing video education programs:
Non-Small Cell Lung Cancer
2.2 Contact hours
Breast Cancer
1.6 Contact hours
Lymphomas and Chronic Lymphocytic Leukemia
2.2 Contact hours
Myeloproliferative Neoplasms
1.6 Contact hours
Ovarian Cancer
1.75 Contact hours
Gastrointestinal Cancers
2.1 Contact hours